Pre-market Hot Trades in US Stocks
Bimergen Energy is up 24.18% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 23, Bimergen Energy announced its current expectations and future plans. Despite the uncertainties and risks associated with these forward-looking statements, the market remains optimistic about its future development, driving the stock price up. The risk factors and uncertainties mentioned in the announcement have led investors to have positive expectations about the company's future growth potential.
</li>
<li>
On February 23, Bimergen Energy's announcement detailed the risk factors in the final prospectus related to its public offering, which has led investors to have positive expectations about the company's future growth potential, driving the stock price up. The energy sector has recently performed strongly, with significant capital inflows.
</li>
</ol>
VenHub Global is down 8.20% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 23, VenHub Global announced the launch of its self-diagnostic robotic technology, causing the stock price to rise by 17%. This technology allows the system to automatically identify performance issues and safely shut down for maintenance while ensuring normal store operations. This move strengthens its platform foundation and supports retailers in accelerating the availability of future autonomous retail stores. Source: RTT News
</li>
<li>
On February 23, VenHub Global issued a press release emphasizing the accuracy and accountability of its information. Source: GlobeNewswire
</li>
<li>
On February 21, the overall market was volatile, with significant stock price fluctuations among multiple companies. Source: RTT News. Macroeconomic volatility has intensified, and risks need to be monitored.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Vir Biotechnology is up 54.78% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 24, Vir Biotechnology entered into a collaboration agreement with Astellas Pharma to advance VIR-5500 for the treatment of prostate cancer. The agreement includes a $335 million upfront payment and recent milestone payments, with Vir eligible for up to $1.37 billion in development, regulatory, and sales milestone payments, as well as double-digit royalties on sales outside the United States. This collaboration has driven the stock price up.
</li>
<li>
On February 24, Vir Biotechnology announced the Phase 1 clinical trial results for VIR-5500, showing dose-dependent anti-tumor activity, with a PSA50 decline of 82% and a PSA90 decline of 53%, and an observed objective response rate of 45% in the ≥3,000 µg/kg dose group. This positive result further boosted market confidence.
</li>
<li>
On February 24, Vir Biotechnology reported fourth-quarter revenue of $64.07 million, a year-over-year increase of 417.9%, exceeding market expectations. This strong financial performance has enhanced investor confidence in the company's future growth
The biotechnology industry faces regulatory risks and high market volatility.
</li>
</ol>
Silo Pharma is up 33.29% in pre-market trading. Based on recent news,
<ol>
<li>
On February 23, Silo Pharma announced a $1 million stock repurchase plan. This plan indicates that management believes the company's stock is undervalued in the current market and aims to enhance shareholder value. Following the announcement, Silo Pharma's stock price surged.
</li>
<li>
On February 23, Silo Pharma released a related announcement through the EDGAR system, further confirming the details of the repurchase plan. This official disclosure boosted market confidence and drove the stock price higher.
</li>
<li>
On February 23, market analysis pointed out that Silo Pharma's repurchase plan is part of the company's capital allocation strategy, aimed at addressing current market conditions and enhancing shareholder value. Analysts believe this move will have a positive impact on the company's stock price. The biopharmaceutical industry has performed strongly recently, increasing investor attention.
</li>
</ol>
Blue Hat is up 30.40% in pre-market trading. Based on recent news,
<ol>
<li>
On February 21, Blue Hat announced a transaction that includes an underwriter's option to purchase an additional 4.8 million units within 15 days, which may deepen dilution. Blue Hat expects this issuance to be completed on February 23, with proceeds to be used for working capital and general corporate purposes, as the company shifts from its traditional augmented reality gaming business to global merchandise trading. This news led to significant stock price fluctuations.
</li>
<li>
On February 21, Blue Hat's stock price fell over 70% on Friday, hitting a 52-week low. According to Benzinga Pro data, Blue Hat Interactive's stock price dropped 75.17% at the time of the announcement, to $0.11.
</li>
<li>
On February 23, analysts' ratings for Blue Hat did not change significantly, but the market's response to its transformation plan remains cautious. Blue Hat's transformation plan has attracted market attention, with trading volume significantly increasing
</li>
</ol>

BESS

VHUB

Bimergen Energy pre-market up 24.18%; VenHub Global pre-market down 8.20%; Vir Biotechnology pre-market up 54.78%; Silo Pharma pre-market up 33.29%; Blue Hat pre-market up 30.40%

Pre-market hot trades in US stocks: Bimergen Energy up 24.18% pre-market; VenHub Global down 8.20% pre-market